PDCD1 and hepatocellular carcinoma: In addition to anti-PD1/CTLA4 immune checkpoint therapy, our study suggests that the combination of anti-checkpoint with anti-MMP9 [51] or anti-TAMs [65] may be more beneficial to patients with T cell dysfunction in HCC.